Back to results
US 2012/0073003 A1Published application
Apobec3 mediated dna editing
AssigneeInstitut Pasteur
InventorsSimon Wain-Hobson, Jean-Pierre Vartanian
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeInstitut Pasteur
InventorsSimon Wain-Hobson, Jean-Pierre Vartanian
Estimating the term…
The present invention relates to methods and compositions for preventing the occurance or progression of a cancer or pre-cancerous condition associated with expression, or over-expression of human cytidine deaminases of the APOBEC3 family. The invention also relates to drug screening assays designed to identify compounds that regulate the activity, or level of expression, of hA3A, hA3C and hA3H. The invention further relates to transgenic mice, as well as cells derived from said mice, that have been genetically engineered to express, or over-express hA3A, hA3C and/or hA3H. Such mice may be utilized to screen for, or identify, compounds that modulate the activity, or expression, of the human cytidine deaminases. The present invention also provides topical compositions such as cosmetic lotion, crème, or sunscreen for use on the skin, which comprise one or more inhibitors of human cytidine deaminase activity. The present invention relates to a double stranded DNA obtained following opening up of its duplex structure, said DNA being edited with cellular protein normally or abnormally expressed in the nucleus of an eukaryotic cell. The mono stranded DNA derived from the said double stranded DNA is a part of the present invention.
A method for identifying a compound that inhibits hA3A, hA3C or hA3H enzyme activity comprising (i) contacting a cell expressing hA3A, hA3C or hA3H with a test compound and substrate and measuring the level of cytidine deaminase activity, (ii) in a separate experiment, contacting a cell expressing hA3A, hA3C or hA3H and substrate and measuring the level of cytidine deaminase activity, where the conditions are essentially the same as in part (i) and then (iii) comparing the level of cytidine deaminase activity measured in part (i) with the level of cytidine deaminase activity in part (ii), wherein a decrease level of cytidine deaminase activity in the presence of the test compound indicates that the test compound is a cytidine deaminase activity inhibitor.
A method for identifying a compound that increases hA3A, hA3C or hA3H enzyme activity comprising (i) contacting a cell expressing hA3A, hA3C or hA3H with a test compound and substrate and measuring the level of cytidine deaminase activity, (ii) in a separate experiment, contacting a cell expressing hA3A, hA3C or hA3H and substrate and measuring the level of cytidine deaminase activity, where the conditions are essentially the same as in part (i) and then (iii) comparing the level of cytidine deaminase activity measured in part (i) with the level of cytidine deaminase activity in part (ii), wherein an increase level of cytidine deaminase activity in the presence of the test compound indicates that the test compound is a cytidine deaminase activity activator.
A transgenic animal expressing a nucleic acid encoding human hA3A, hA3C or hA3H, wherein expression of said hA3A, hA3C or hA3H results in an increase in DNA editing.
A method for identifying a carcinogenic compound comprising (i) contacting a cell expressing hA3A, hA3C or hA3H with a compound suspected of being carcinogenic and substrate and measuring the level of cytidine deaminase activity, (ii) in a separate experiment, contacting a cell expressing hA3A, hA3C or hA3H and substrate and measuring the level of cytidine deaminase activity, where the conditions are essentially the same as in part (i) and then (iii) comparing the level of cytidine deaminase activity measured in part (i) with the level of cytidine deaminase activity in part (ii), wherein an increase level of cytidine deaminase activity in the presence of the test compound indicates that the test compound is carcinogenic compound.
A double stranded DNA following opening up of its duplex structure, said DNA being edited with a cellular protein normally or abnormally expressed in the nucleus of an eukaryotic cell.
A method for detecting cytidine deamination in HPV DNA comprising:
Dependencies are inferred from the claim text.